TRIMB, UAB - financials and debts

Company age: 12 y. 9 mo.

Update

TRIMB - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 562,267 674,630 1,070,983 1,563,181 1,951,020 1,706,461 2,674,599 3,578,251
Profit before tax -98,590 -75,825 90,849 45,639 -55,023 154,463 36,592 -91,815
Net profit -98,590 -75,825 86,045 43,313 -55,023 147,552 31,966 -90,820
Equity -192,343 -268,168 -182,123 -138,810 -193,833 538,450 570,416 480,596
Liabilities 281,078 465,676 731,023 714,588 1,010,694 268,850 553,896 540,687
Non-current assets 369 176 1 0 0 0 52,919 141,057
Current assets 88,366 377,306 543,623 824,832 982,766 903,038 1,060,506 1,267,877
Total assets 88,735 377,482 543,624 824,832 982,766 903,038 1,113,425 1,408,934
Taxes paid
STI taxes - - - - - 57,576 83,428 227,502
Social insurance contributions - - - - - 27,050 130,184 249,690
Financial indicators
Revenue change y/y -6.5% +20.0% +58.8% +46.0% +24.8% -12.5% +56.7% +33.8%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. -111.1% -20.1% 15.8% 5.3% -5.6% 16.3% 2.9% -6.4%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. - - - - - 27.4% 5.6% -18.9%
Profit margin Net profit margin. Shows the overall profitability of the company. -17.5% -11.2% 8.0% 2.8% -2.8% 8.6% 1.2% -2.5%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. -17.5% -11.2% 8.5% 2.9% -2.8% 9.1% 1.4% -2.6%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. - - - - - 0.5 1.0 1.1
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 182,359 165,217 257,034 390,795 477,805 417,912 163,751 112,112

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

TRIMB - Social security debts

From To Debt, €
2025-05-19 2025-05-26 10.60
2024-11-18 2024-11-21 27.06
2024-08-20 2024-08-22 11957.87
2024-08-19 2024-08-19 11771.09
2024-07-24 2024-07-25 19.03
2024-06-18 2024-06-20 8774.26
2024-05-16 2024-05-16 12504.36
2024-04-16 2024-04-18 1333.17
2023-02-17 2023-03-21 3.57
2023-02-06 2023-02-14 0.35
2023-01-17 2023-02-03 0.35
2022-12-16 2023-01-15 0.37
2022-11-21 2022-12-14 0.39
2022-11-17 2022-11-18 0.39
2022-10-18 2022-11-14 0.40
2022-09-16 2022-10-13 0.42
2022-08-23 2022-09-14 0.44
2022-07-25 2022-08-02 0.46
2022-06-16 2022-06-19 63.59
2022-05-17 2022-06-02 1.11
2022-04-28 2022-05-12 1.11
2021-12-16 2022-01-02 2.08

TRIMB - VMI tax arrears

The company had no tax arrears (debts) to the State Tax Inspectorate

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
TRIMB, UAB (code 303208187) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In the latest financial year 2025, the company generated revenue of €3.58M, up 33.8% year on year and 109.7% over two years, showing strong top-line expansion. However, profitability weakened materially: net profit fell to a loss of €90.8K in 2025, compared with a profit of €32.0K in 2024 and €147.6K in 2023. The 2025 net profit margin was -2.5%, after 1.2% in 2024 and 8.6% in 2023. The balance sheet also expanded, with total assets increasing to €1.41M, equity to €480.6K and liabilities to €540.7K. The equity ratio stood at 34.1% and debt-to-equity at 1.13. Asset turnover was 2.54x, indicating efficient use of assets in revenue generation. Revenue per employee was €115.4K, while profit per employee was -€2.9K, reflecting the weaker earnings outcome in 2025.